Literature DB >> 12970907

Effect of enterokinetic prucalopride on intestinal motility in fast rats.

Hui-Bin Qi1, Jin-Yan Luo, Xin Liu.   

Abstract

AIM: To evaluate the effects of prucalopride on intestinal prokinetic activity in fast rats and to provide experimental basis for clinical treatment of gastrointestinal motility diseases.
METHODS: Gastrointestinal propulsion rate was measured by the migration rate of activated charcoal, which reflexes gastrointestinal motility function. 120 Spraque-Dawley rats were randomly divided into four groups and received an intravenous injection of physiological saline (served as control), prucalopride 1 mg/kg, prucalopride 2 mg/kg and cisapride 1 mg/kg, respectively. The gastrointestinal propulsion rate was measured 1, 2 or 4 hours after intravenous injection of the drugs.
RESULTS: Significant accelerations of gastrointestinal propulsion rate in prucalopride 1 mg/kg and 2 mg/kg groups were found compared with control group at 2 and 4 hours(83.2 %+/-5.5 %, 81.7 %+/-8.5 % vs 70.5 %+/-9.2 %, P<0.01; 91.2 %+/-2.2 %, 91.3 %+/-3.9 % vs 86.8 %+/-2.6 %, P<0.01). The gastrointestinal propulsion rates at 1, 2 or 4 hours were faster in prucalopride 1 mg/kg and 2 mg/kg groups than in cisapride group (84.0 %+/-11.7 %, 77.1 %+/-11.9 % vs 66.3 %+/-13.6 %, P<0.01, P<0.05; 83.2 %+/-5.5 %, 81.7 %+/- 8.5 % vs 75.4 %+/-5.9 %, P<0.01, P<0.05; 91.2 %+/-2.2 %, 91.3 %+/-3.9 % vs 88.6 %+/-3.5 %,P<0.05, P<0.05). No difference of gastrointestinal propulsion rate was found between prucalopride 1 mg/kg group and prucalopride 2 mg/kg group (P>0.05).
CONCLUSION: Prucalopride accelerates intestinal motility in fast rats, and has no dose dependent effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970907      PMCID: PMC4656675          DOI: 10.3748/wjg.v9.i9.2065

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  Serotoninergic neuroenteric modulators.

Authors:  N J Talley
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

2.  5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study.

Authors:  N H Prins; A van Der Grijn; R A Lefebvre; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.

Authors:  E P Bouras; M Camilleri; D D Burton; S McKinzie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

4.  Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers.

Authors:  A C Poen; R J Felt-Bersma; P A Van Dongen; S G Meuwissen
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

5.  Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury.

Authors:  K Krogh; M Bach Jensen; P Gandrup; S Laurberg; J Nilsson; R Kerstens; M De Pauw
Journal:  Scand J Gastroenterol       Date:  2002-04       Impact factor: 2.423

Review 6.  Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

Authors:  F De Ponti; M Tonini
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Idiopathic constipation: too few stools and too little knowledge.

Authors:  M R Briejer; J A Schuurkes; S K Sarna
Journal:  Trends Pharmacol Sci       Date:  1999-01       Impact factor: 14.819

8.  Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.

Authors:  C E J Sloots; A C Poen; R Kerstens; M Stevens; M De Pauw; J C Van Oene; S G M Meuwissen; R J F Felt-Bersma
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

9.  Prucalopride, a systemic enterokinetic, for the treatment of constipation.

Authors:  A V Emmanuel; A J Roy; T J Nicholls; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

10.  Regulation of the enteric nervous system in the colon of patients with slow transit constipation.

Authors:  Ryouichi Tomita; Katsuhisa Tanjoh; Shigeru Fujisaki; Tarou Ikeda; Masahiro Fukuzawa
Journal:  Hepatogastroenterology       Date:  2002 Nov-Dec
View more
  5 in total

1.  5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.

Authors:  M Cachard-Chastel; F Lezoualc'h; I Dewachter; C Deloménie; S Croes; H Devijver; M Langlois; F Van Leuven; S Sicsic; A M Gardier
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

2.  Pathophysiological significance of a reaction in mouse gastrointestinal tract associated with delayed-type hypersensitivity.

Authors:  Wan-Gui Yu; Ping Lin; Hui Pan; Lan Xiao; En-Cong Gong; Lin Mei
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 3.  Preclinical experimental models for assessing laxative activities of substances/products under investigation: a scoping review of the literature.

Authors:  Patiwat Kongdang; Dumnoensun Pruksakorn; Nut Koonrungsesomboon
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

4.  Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.

Authors:  Banny S Wong; Noriaki Manabe; Michael Camilleri
Journal:  Clin Exp Gastroenterol       Date:  2010-05-24

5.  The effects of prucalopride on postoperative ileus in guinea pigs.

Authors:  Soo Jung Park; Eun Ju Choi; Young Hoon Yoon; Hyojin Park
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.